HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

Abstract
The mammalian innate immune system recognizes pathogens via a series of pattern-recognition receptors such as the toll-like receptors (TLR) that interact with pathogen-associated molecular patterns (PAMPs) and lead to the rapid activation of innate immune cells. In this study, we compared the efficacy of CpG ODN (a TLR9 agonist) and resiquimod (R-848; a TLR7/8 agonist) for topical immunoprophylaxis or immunotherapy of vaginal herpes simplex virus type 2 (HSV-2) infection in mice. Efficacy against HSV infection was observed with CpG ODN but less so with R-848, even after repeated administrations. Intravaginal (IVAG) administration of CpG ODN resulted in strong local but relatively weak systemic immune activation, as determined by levels of the chemokines IP-10, MIG and I-TAC in vaginal tissue and plasma, respectively. In contrast, IVAG administration of R-848 resulted in high levels of plasma IP-10, similar to those seen after parenteral administration, but overall, weaker or shorter-lived local immune responses than obtained with CpG ODN. These findings suggest that differences in biodistribution and sites of immune activation between CpG ODN and R-848 after IVAG delivery account for differences in efficacy, and demonstrate the need for local mucosal innate activation for protection against HSV-2.
AuthorsMichael J McCluskie, Janna L M Cartier, Amy J Patrick, Dusan Sajic, Risini D Weeratna, Kenneth L Rosenthal, Heather L Davis
JournalAntiviral research (Antiviral Res) Vol. 69 Issue 2 Pg. 77-85 (Feb 2006) ISSN: 0166-3542 [Print] Netherlands
PMID16377001 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • CPG-oligonucleotide
  • Imidazoles
  • Oligodeoxyribonucleotides
  • resiquimod
Topics
  • Adjuvants, Immunologic (administration & dosage, therapeutic use)
  • Animals
  • CpG Islands
  • Female
  • Herpes Genitalis (drug therapy, prevention & control, virology)
  • Herpesvirus 2, Human (drug effects, pathogenicity)
  • Imidazoles (administration & dosage, therapeutic use)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Oligodeoxyribonucleotides (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Vagina (virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: